Insmed Incorporated (INSM) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Bridgewater, NJ, United States. Le PDG actuel est William H. Lewis.
INSM a date d'introduction en bourse 2000-06-01, 1,271 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $33.07B.
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company's commercial product, ARIKAYCE, is an inhaled antibiotic combination therapy approved for treating Mycobacterium avium complex lung disease in adults. Insmed's pipeline includes Brensocatib, an oral inhibitor of dipeptidyl peptidase 1 being developed for bronchiectasis and neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treatment candidate for pulmonary arterial hypertension and other rare pulmonary disorders. Founded in 1988 and headquartered in Bridgewater, New Jersey, the company specializes in addressing unmet medical needs in rare respiratory and systemic diseases.
